[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20034204D0 - Farmasöytiske kombinasjoner til behandling av kreft - Google Patents

Farmasöytiske kombinasjoner til behandling av kreft

Info

Publication number
NO20034204D0
NO20034204D0 NO20034204A NO20034204A NO20034204D0 NO 20034204 D0 NO20034204 D0 NO 20034204D0 NO 20034204 A NO20034204 A NO 20034204A NO 20034204 A NO20034204 A NO 20034204A NO 20034204 D0 NO20034204 D0 NO 20034204D0
Authority
NO
Norway
Prior art keywords
cancer
treatment
pharmaceutical combinations
formula
therapeutic agent
Prior art date
Application number
NO20034204A
Other languages
English (en)
Other versions
NO20034204L (no
Inventor
Francis J Giles
Hagop M Kantarjian
Jacques Jolivet
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of NO20034204D0 publication Critical patent/NO20034204D0/no
Publication of NO20034204L publication Critical patent/NO20034204L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20034204A 2001-03-23 2003-09-22 Farmasöytiske kombinasjoner til behandling av kreft NO20034204L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27797501P 2001-03-23 2001-03-23
US33060101P 2001-10-25 2001-10-25
PCT/CA2002/000426 WO2002076472A2 (en) 2001-03-23 2002-03-25 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs

Publications (2)

Publication Number Publication Date
NO20034204D0 true NO20034204D0 (no) 2003-09-22
NO20034204L NO20034204L (no) 2003-11-21

Family

ID=26958821

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034204A NO20034204L (no) 2001-03-23 2003-09-22 Farmasöytiske kombinasjoner til behandling av kreft

Country Status (13)

Country Link
US (2) US6800639B2 (no)
EP (1) EP1370270B1 (no)
JP (1) JP4391087B2 (no)
KR (1) KR20040018341A (no)
AT (1) ATE450265T1 (no)
CA (1) CA2441568A1 (no)
DE (1) DE60234577D1 (no)
HU (1) HUP0400314A3 (no)
MX (1) MXPA03008623A (no)
NO (1) NO20034204L (no)
NZ (1) NZ528394A (no)
PL (1) PL365285A1 (no)
WO (1) WO2002076472A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
CA2493023C (en) * 2002-07-30 2012-01-31 Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments
US20040192652A1 (en) * 2002-12-06 2004-09-30 Giles Francis J. Pharmaceutical combinations and methods for the treatment of leukemia
AU2004226888B2 (en) * 2003-04-02 2009-09-10 Celator Pharmaceuticals, Inc. Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance
PT2368554E (pt) 2003-04-08 2015-02-06 Progenics Pharm Inc Formulações farmacêuticas que contêm metilnaltrexona
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
SI2263694T1 (sl) * 2003-09-25 2013-09-30 Astellas Pharma Inc. Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
BRPI0608818A2 (pt) 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
CN103028120B (zh) 2005-09-12 2015-08-12 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
KR20090057050A (ko) * 2006-09-01 2009-06-03 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 암치료를 위한 트록사시타빈 전구약물
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
ES2570374T3 (es) 2007-03-29 2016-05-18 Progenics Pharm Inc Antagonistas del receptor opioide periférico y usos de los mismos
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
TW201216958A (en) 2008-01-11 2012-05-01 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20100004193A1 (en) * 2008-07-07 2010-01-07 Fondazione Per La Ricerca Biomedica Avanzata Onlus - Istituto Veneto Di Medicina Molecolare Combination therapy
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
TWI558724B (zh) 2010-04-12 2016-11-21 瑞塔醫藥有限責任公司 利用抗氧化發炎調節劑治療肥胖之方法
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
ATE442151T1 (de) 1999-03-29 2009-09-15 Shire Canada Inc Verwendung von cytidinderivaten zur behandlung von leukämie
NZ537432A (en) * 2000-10-13 2005-05-27 Shire Biochem Inc Dioxolane analogs for improved inter-cellular delivery
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine

Also Published As

Publication number Publication date
NZ528394A (en) 2005-06-24
MXPA03008623A (es) 2004-05-21
HUP0400314A3 (en) 2006-02-28
HUP0400314A2 (hu) 2004-08-30
PL365285A1 (en) 2004-12-27
US6800639B2 (en) 2004-10-05
ATE450265T1 (de) 2009-12-15
KR20040018341A (ko) 2004-03-03
NO20034204L (no) 2003-11-21
WO2002076472A2 (en) 2002-10-03
US20050004081A1 (en) 2005-01-06
EP1370270A2 (en) 2003-12-17
JP2004525142A (ja) 2004-08-19
WO2002076472A3 (en) 2003-04-10
EP1370270B1 (en) 2009-12-02
JP4391087B2 (ja) 2009-12-24
US20030083316A1 (en) 2003-05-01
CA2441568A1 (en) 2002-10-03
DE60234577D1 (de) 2010-01-14

Similar Documents

Publication Publication Date Title
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
MXPA04012965A (es) Inhibidores virales.
BR0012450A (pt) Benzimidazóis substituìdos
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
ATE512976T1 (de) Hemmer des hepatitis-c-virus
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
DE50310516D1 (de) Fredericamycin-derivate
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
SE0101932D0 (sv) Pharmaceutical combinations
EA200200922A1 (ru) Композиция, включающая камптотецин и производное пиримидина, для лечения рака
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
MXPA04005809A (es) Inhibidores de proteinas quinasas.
DE60128100D1 (de) Analgetisches arzneimittel
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
SE0004101D0 (sv) New use
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application